Filter by
Filter by
Chemoradiation with Hypofractionated Proton Therapy in Stage II-III Non-Small Cell Lung Cancer: A Proton Collaborative Group Phase 1/2 Trial.
This study presented outcomes of a prospective multicenter trial with an early closure. Twenty-eight patients with stage II or III unresectable NSCLC were...
Exposure of the heart in lung cancer radiation therapy: A systematic review of heart doses published during 2013 to 2020.
Data of 140 dosimetry studies was analyzed. In the 105 non-SABR studies, the average MHD was similar between IMRT and 3DCRT (10.9 Gy versus 10.6 Gy) and lower...
Effects of lymphopenia on survival in proton therapy with chemotherapy for non-small cell lung cancer.
With data of 41 patients with stage III NSCLC who received PBT of 74 GyE with concurrent chemotherapy, this study reported that bone V5-20 and lung V5-50 were...
Efficacy and safety of particle therapy for inoperable stage II-III non-small cell lung cancer: a systematic review and meta-analysis.
This review provided systematic evidence for evaluating the efficacy and safety of particle therapy for inoperable locally advanced NSCLC. Based on 19 studies...
ASTRO Radiation Therapy Summary of the ASCO Guideline on Management of Stage III Non-Small Cell Lung Cancer.
Based on the ‘Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline’, this summary document makes recommendations directly related to RT for the...
Future Perspectives of Proton Therapy in Minimizing the Toxicity of Breast Cancer Radiotherapy.
A review article compared the clinical evidence including the parameters of the dose distribution in organs at risk, such as the heart, blood vessels, and lungs...
A retrospective study of adjuvant proton radiotherapy for breast cancer after lumpectomy: a comparison of conventional-dose and hypofractionated dose.
Fifty patients were treated with PT using two different regimens following lumpectomy. 14 patients received IMPT to a total dose of 50 Gy in 25 fractions...